Drugs / modified T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01416974 | Aug 2011 → Jan 2019 | leukemia | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | modified T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01416974 ↗ |
| Modality | Cell therapy | “specially prepared cells collected from the patients called "modified T cells."” NCT01416974 ↗ |
| Target | CD19 | “genetically targeted to the B cell specific antigen CD19” NCT01416974 ↗ |